These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33832341)

  • 21. Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin Attenuates Sorafenib-Induced Myocardial Inflammation and Toxicity.
    Liu CH; Ho YC; Lee WC; Huang CY; Lee YK; Hsieh CB; Huang NC; Wu CC; Nguyen NUN; Hsu CC; Chen CH; Chen YC; Huang WC; Lu YY; Fang CC; Chang YC; Chang CL; Tsai MK; Wen ZH; Li CZ; Li CC; Chuang PK; Yang SM; Chu TH; Huang SC
    Environ Toxicol; 2024 Nov; 39(11):4844-4858. PubMed ID: 38884142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview ofits Chemistry, Pharmacology, and Toxicology.
    Yadav J; Ahsan F; Panda P; Mahmood T; Ansari VA; Shamim A
    Curr Diabetes Rev; 2024; 20(10):e230124226010. PubMed ID: 38265382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.
    Shiraki A; Oyama JI; Shimizu T; Nakajima T; Yokota T; Node K
    Eur J Pharmacol; 2022 Sep; 931():175194. PubMed ID: 35987253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
    Kidokoro K; Cherney DZI; Bozovic A; Nagasu H; Satoh M; Kanda E; Sasaki T; Kashihara N
    Circulation; 2019 Jul; 140(4):303-315. PubMed ID: 30773020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure.
    Asil H; Demiryürek AT; Düzen IV; Büyükcelebi O; Saracaloglu A; Demirkiran C; Demiryürek Ş
    Eur J Pharmacol; 2024 Nov; 982():176934. PubMed ID: 39182552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
    Matharu K; Chana K; Ferro CJ; Jones AM
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling.
    Shentu Y; Li Y; Xie S; Jiang H; Sun S; Lin R; Chen C; Bai Y; Zhang Y; Zheng C; Zhou Y
    Int Immunopharmacol; 2021 Apr; 93():107374. PubMed ID: 33517222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
    Shao SC; Chang KC; Lin SJ; Chang SH; Hung MJ; Chan YY; Lai EC
    Cardiovasc Diabetol; 2021 Oct; 20(1):213. PubMed ID: 34688282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
    Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
    Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
    Gordon M; Meagher P; Connelly KA
    Can J Diabetes; 2021 Aug; 45(6):553-556. PubMed ID: 33388277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
    Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
    Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
    Ni XY; Feng XJ; Wang ZH; Zhang Y; Little PJ; Cao Y; Xu SW; Tang LQ; Weng JP
    Acta Pharmacol Sin; 2024 Aug; 45(8):1604-1617. PubMed ID: 38589689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart.
    Karpushev AV; Mikhailova VB; Klimenko ES; Kulikov AN; Ivkin DY; Kaschina E; Okovityi SV
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Empagliflozin: current indications and aspects for daily clinical practice].
    Iacoviello M; Aspromonte N
    G Ital Cardiol (Rome); 2023 Dec; 24(12 Suppl 3):3S-12S. PubMed ID: 38226446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.